

Minerva Access is the Institutional Repository of The University of Melbourne

Author/s:

Zhao, Y;Zhang, J;Zamora, J;Vogel, JP;Souza, JP;Jayaratne, K;Ganchimeg, T;Ortiz-Panozo, E;Hernandez, B;Oladapo, OT;Torloni, MR;Morisaki, N;Mori, R;Pileggi-Castro, C;Tunçalp, Ö;Shen, X;Betrán, AP

Title:

Increases in Caesarean Delivery Rates and Change of Perinatal Outcomes in Low- and Middle-Income Countries: A Hospital-Level Analysis of Two WHO Surveys

Date:

2017-07-01

Citation:

Zhao, Y., Zhang, J., Zamora, J., Vogel, J. P., Souza, J. P., Jayaratne, K., Ganchimeg, T., Ortiz-Panozo, E., Hernandez, B., Oladapo, O. T., Torloni, M. R., Morisaki, N., Mori, R., Pileggi-Castro, C., Tunçalp, Ö., Shen, X. & Betrán, A. P. (2017). Increases in Caesarean Delivery Rates and Change of Perinatal Outcomes in Low- and Middle-Income Countries: A Hospital-Level Analysis of Two WHO Surveys. *Paediatric and Perinatal Epidemiology*, 31 (4), pp.251-262. <https://doi.org/10.1111/ppe.12363>.

Persistent Link:

<https://hdl.handle.net/11343/292870>

1

2 PROF. JUN ZHANG (Orcid ID : 0000-0002-9926-5986)

3 DR. NAHO MORISAKI (Orcid ID : 0000-0001-6151-4513)

4

5

6 Article type : Original Article

7

8

9 Title page

10 **Increases in caesarean section rates and change of perinatal outcomes**  
11 **in low- and middle-income countries: a hospital-level analysis of two**  
12 **WHO surveys**

13 Yanjun Zhao,<sup>1,2</sup> Jun Zhang,<sup>1</sup> Javier Zamora,<sup>3</sup> Joshua Peter Vogel,<sup>4</sup> João Paulo Souza,<sup>5</sup> Kapila  
14 Jayaratne,<sup>6</sup> Togoobaatar Ganchimeg,<sup>7</sup> Eduardo Ortiz-Panozo,<sup>8</sup> Bernardo Hernandez,<sup>9</sup> Olufemi  
15 Taiwo Oladapo,<sup>4</sup> Maria Regina Torloni,<sup>10</sup> Naho Morisaki,<sup>11</sup> Rintaro Mori,<sup>12</sup> Cynthia  
16 Pileggi-Castro,<sup>13</sup> Özge Tunçalp,<sup>4</sup> Xiaoming Shen,<sup>1</sup> Ana Pilar Betrán<sup>4</sup>

17

18 <sup>1</sup>MOE-Shanghai Key Laboratory of Children's Environmental Health, Xinhua  
19 Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

20 Email: 13524813362@163.com (Yanjun Zhao); zhangjunjim@gmail.com (Jun Zhang);

21 xmshen@shsmu.edu.cn (Xiaoming Shen)

22 <sup>2</sup> Department of Child Health Care, Shanghai Children's Hospital, Shanghai Jiao Tong  
23 University, Shanghai, China

24 <sup>3</sup>Clinical Biostatistics Unit, Hospital Ramon y Cajal, CIBER Epidemiology and

This is the author manuscript accepted for publication and has undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: [10.1111/ppe.12363](https://doi.org/10.1111/ppe.12363)

This article is protected by copyright. All rights reserved

25 Public Health, Madrid, Spain. Women Health Research Unit, Centre for Primary Care  
26 and Public Health, Queen Mary University, London, UK

27 Email:javier.zamora@hrc.es

28 <sup>4</sup>UNDP • UNFPA • UNICEF • WHO • World Bank Special Programme of Research,  
29 Development and Research Training in Human Reproduction (HRP), Department of  
30 Reproductive Health and Research, World Health Organization, Geneva, Switzerland

31 Email:betrana@who.int (Ana Pilar Betrán); vogeljo@who.int (Joshua Peter Vogel);  
32 oladapoo@who.int (Olufemi Taiwo Oladapo); tuncalpo@who.int (Özge Tunçalp)

33 <sup>5</sup>Department of Social Medicine, Ribeirão Preto Medical School, University of São  
34 Paulo, Ribeirão Preto, SP, Brazil

35 Email:jpsouza@fmrp.usp.br

36 <sup>6</sup>Family Health Bureau, Ministry of Health, Colombo, Sri Lanka

37 Email:kapjay613@gmail.com

38 <sup>7</sup>Faculty of Medicine, University of Tsukuba, Tsukuba, Japan

39 Email:ganchimeg.tb@gmail.com

40 <sup>8</sup>Center for Population Health Research, National Institute of Public Health,  
41 Cuernavaca, Mexico

42 Email:eduardo.ortiz@insp.mx

43 <sup>9</sup>Institute for Health Metrics and Evaluation, University of Washington, Seattle, WA,  
44 USA

45 Email:bhp3@uw.edu

46 <sup>10</sup>Evidence Based Health Care Post Graduate Program, Department of Medicine, Sao  
47 Paulo Federal University, Sao Paulo, Brazil.

48 Email: torlonimr@gmail.com

49 <sup>11</sup>Division of Lifecourse Epidemiology, Department of Social Medicine, National  
50 Center for Child Health and Development, Tokyo, Japan

51 Email:morisaki-n@ncchd.go.jp

52 <sup>12</sup> Department of Health Policy, National Center for Child Health and  
53 Development, Tokyo, Japan

54 Email:rintaromori@gmail.com

55 <sup>13</sup>Department of Pediatrics, Ribeirão Preto Medical School, University of São Paulo,  
56 Ribeirão Preto, SP, Brazil  
57 Email: cynthiapileggi@gmail.com

58

59 Correspondence to:

60 Dr Jun Zhang,

61 Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, 1665 Kong  
62 Jiang Road, Shanghai, China

63 Email: zhangjunjim@gmail.com

64 Telephone: +86-21-2507-8871

65 Fax: +86-21-2507-8875

## 66 **Abstract**

### 67 **Background**

68 Maternal and neonatal outcomes have improved substantially. During the same period,  
69 the caesarean section (CS) rate soared. The aim of this analysis was to determine  
70 whether an increase in CS rate was associated with an improvement in perinatal  
71 outcome at an institutional level in low- and middle-income countries.

### 72 **Methods**

73 The WHO Global Survey on Maternal and Perinatal Health (WHOGS) and the WHO  
74 Multi-country Survey on Maternal and Newborn Health (WHOMCS) were two  
75 multi-country, facility-based cross-sectional surveys conducted in 2004–2008 and  
76 2010–2011, respectively. The increase in CS rate and the change of incidence of  
77 adverse perinatal outcomes were calculated using a two-point estimator of percent  
78 change annualized (PCA) method. Perinatal, maternal and neonatal composite indexes  
79 were used as the outcomes. A linear mixed model was used to assess the association  
80 between the change of CS rate and the change of perinatal outcome.

### 81 **Results**

This article is protected by copyright. All rights reserved

82 A total of 259 facilities in 20 countries participated in both surveys, with 217844  
83 women in WHOGS and 227734 women in WHOMCS. The CS rate in these facilities  
84 increased by 3.99% annually, on average, while the incidence of adverse perinatal  
85 outcomes decreased by 4.59% annually. However, after we adjusted for potential  
86 confounders, no significant association was found between the increase in CS rate and  
87 the change of adverse outcome index, regardless of whether starting CS rates were  
88 already high (above 10%) or not.

## 89 **Conclusions**

90 In low- and middle-income countries, the increases in CS rates were not associated  
91 with better perinatal outcomes regardless of whether the starting CS rate was already  
92 high or not.

## 93 **Keywords**

94 Caesarean section rate, perinatal, adverse outcomes, low and middle income countries

## 95 **Introduction**

96 Maternal health has undergone a dramatic improvement worldwide in the past  
97 two to three decades. The latest report shows that globally there were an estimated  
98 303 000 maternal deaths in 2015, a decline of 43.9% from 1990 levels.<sup>1</sup> Global  
99 perinatal mortality statistics have also improved.<sup>2-4</sup> Neonatal and infant mortality rate  
100 declined by 36% and 46% in low-income countries, and 43% and 58% in high-income  
101 countries from 1990 to 2012.<sup>5</sup> Meanwhile, caesarean section (CS) rates have increased  
102 substantially, even tripled or quadrupled, in many parts of the world.<sup>6</sup>

103 Have increased CS rates contributed to better maternal and neonatal outcomes,  
104 and if so by how much? Studies of the relationship between CS rate and mortality  
105 have yielded inconsistent results.<sup>7</sup> A recent cross-sectional, ecological study  
106 estimating annual CS rates from data collected during 2005 to 2012 for all 194 World  
107 Health Organization(WHO) member states, suggested that national CS rates of up to  
108 approximately 19 per 100 live births were associated with lower maternal or neonatal

109 mortality among WHO member states. Higher CS rates were not correlated  
110 with maternal or neonatal mortality at a country level.<sup>8</sup> Some other population-based  
111 ecological studies suggest that when a national CS rate is below 10%, an increase in  
112 the CS rate is associated with a decrease in maternal and neonatal mortality.<sup>9</sup> Further  
113 increases in national CS rates beyond 10% are not associated with further reductions  
114 in mortality, when socioeconomic conditions are adjusted for.<sup>9</sup> This phenomenon has  
115 been consistently demonstrated with data from both high and low-income countries,  
116 and in cross-sectional and longitudinal analyses.<sup>9,10</sup>

117 These ecological studies have been limited to using national rates of CS and  
118 maternal and neonatal mortality, as these measures are routinely reported in civil vital  
119 registration systems and readily available for analysis. Although mortality rates are  
120 generally good indicators for overall maternal and neonatal health at a country level,  
121 other outcomes such as maternal and neonatal severe morbidity,<sup>11-13</sup> and quality of life  
122 are also important, particularly as maternal and newborn outcomes are improving<sup>14,15</sup>  
123 (i.e., mortality decreased substantially, morbidity become more sensitive indicator).  
124 Unfortunately, morbidity data are generally unavailable at a national level, as are data  
125 on potential confounders. Where such data exist, comparisons are often not possible  
126 due to the lack of standardized definitions and outcomes. More evidence is needed to  
127 examine whether CS rate is associated with less severe maternal and neonatal  
128 outcomes. The aim of this analysis is to determine whether an increase in CS rate was  
129 associated with an improvement in maternal and neonatal morbidity and mortality  
130 outcomes at an institutional level in 20 low- and middle-income countries that  
131 participated in two consecutive WHO surveys.<sup>16-18</sup>

132

## 133 **Methods**

### 134 **Design and setting**

135 Data for this secondary analysis were derived from two large, cross-sectional,  
136 facility-based surveys of maternal and perinatal health: the WHO Global Survey of  
137 Maternal and Perinatal Health (WHOGS) and the WHO Multi-Country Survey of  
138 Maternal and Newborn Health (WHOMCS). Detailed descriptions of these studies are

139 available elsewhere.<sup>16-18</sup> Briefly, the WHOGS was conducted to examine the  
140 association of the mode of delivery and maternal and perinatal outcomes in 373 health  
141 facilities in 24 countries from Africa and Latin America (2004–2005) and Asia  
142 (2007–2008). A stratified, multistage cluster sampling strategy was applied to select  
143 the countries, provinces and health facilities.<sup>16</sup> According to this scheme, the first  
144 stage of sampling consisted of countries. This selection was stratified by the WHO  
145 regions and the levels of under-five child and adult mortality. Fourteen sub-regions  
146 were used to frame the first stage of sampling. From each sub-region, a total of four  
147 countries were selected at random for participation in the study, with probability  
148 proportional to the country population. When the total number of countries was less  
149 than four in any sub-region, all the countries were included. This process resulted in  
150 12 sub-regions having four countries each and two sub-regions having three countries  
151 each. A total of 54 countries were initially pre-selected, but, due to operational and  
152 budgetary reasons, the WHOGS was implemented in 24 countries from Africa, Asia  
153 and Latin America plus Canada. The second sampling stage consisted of randomly  
154 selection of two provinces/states (with probability also proportional to the population  
155 size), in addition to the country capital city in these 24 countries. A tertiary sampling  
156 stage (below the province/state level) was used for very large provinces/states. For the  
157 latter (e.g. Mexico City and Beijing), a fourth sampling stage was implemented. Once  
158 the geographical areas were selected, seven health facilities with a minimum of 1,000  
159 deliveries per year were randomly selected from each of these areas. If there were less  
160 than 7 facilities, all facilities of that area were selected. Within each selected facility,  
161 detailed information on all births during a specified period was collected before death,  
162 hospital discharge or up to seven days postpartum (whichever came first) by trained  
163 health professional staff, with a total number of 287036 women (290610 births). Since  
164 there was no individual follow-up of women or newborns after hospital discharge,  
165 data on newborn and maternal status were only collected from the hospital medical  
166 records or staff during the early postpartum period or intensive care units.

167 In 2010–2011, WHOMCS was conducted as a subsequent survey based on the  
168 WHOGS settings and added seven new countries using the same sampling

169 methodology. WHOGS countries were invited to participate in the WHOMCS. Two  
170 countries were unable to join. In total, 359 facilities across 29 countries from Africa,  
171 Asia, Latin America, and the Middle East participated. WHOMCS aimed to examine  
172 severe maternal and newborn outcomes and maternal near miss cases and deaths  
173 regardless of gestational age and mode of delivery (i.e., abortion, ectopic pregnancies).  
174 The study included 314623 women (318534 births). Data collection was conducted in  
175 each facility for a period of 2–4 months, and the study was conducted between May  
176 2010 and December 2011. In addition, in both surveys, institutional information on  
177 the availability of obstetric and newborn services, laboratory tests, and human and  
178 training resources were also collected.

179 The technical content of both protocols was reviewed by specialist panels at the  
180 UNDP/UNFPA/UNICEF/WHO/World Bank Special Programme of Research,  
181 Development and Research Training in Human Reproduction. The Specialist Panel on  
182 Epidemiological Research reviewed and approved the WHOGS study protocol for  
183 technical content; the Research Project Review Panel (name of panel was changed in  
184 2010) reviewed and approved the technical content of the WHOMCS. Both surveys  
185 had ethical approval by the WHO Ethics Review Committee, and the relevant  
186 authorities and institutional review boards in all participating countries.

#### 187 **Data quality**

188 In both studies, a data form was developed and pilot tested. In addition, a Manual of  
189 Operations was developed to guide a structured medical record data abstraction  
190 process by data collectors. This manual minimized the need for judgment and  
191 interpretation by the data collectors. Where incomplete data were identified, data  
192 collectors could verify with medical staff. Validity and random cross-checks were  
193 conducted to ensure quality of entered data.

#### 194 **Study population**

195 In order to be included in this analysis, a facility must have participated in both  
196 WHOGS and WHOMCS and had more than 100 deliveries in each survey. We  
197 excluded women whose gestational age at delivery was less than 22 weeks or  
198 unknown, or with missing information on exposure and outcome variables of interest:

199 delivery mode, five-minute Apgar score, maternal blood transfusion, maternal  
200 admission to ICU/special care unit, newborn status at hospital discharge or on the  
201 seventh day of life (alive/dead), neonatal conditions at birth(alive/fresh stillbirth) and  
202 maternal status at hospital discharge or on the seventh day postpartum if still in  
203 hospital (alive/dead). Most countries participated in both surveys were low- and  
204 middle-income countries, except Japan. Because we were interested in low- and  
205 middle-income countries in this study, we excluded Japan for further analysis. In  
206 addition, the surgical capacity of participating facilities in Angola had a significant  
207 change between the two surveys, and the quality of gestational age data in the  
208 WHOGS was poor.<sup>19</sup> Therefore, we excluded that country, leaving 259 facilities from  
209 20 low- and middle-income countries which participated in both surveys for further  
210 analysis.

#### 211 **Variables and definitions**

212 We used individual data on demographic characteristics, maternal risks, mode of  
213 delivery, pregnancy events and perinatal outcomes. The main exposure of interest in  
214 our study was CS as final mode of delivery. We used the following information as the  
215 main potential confounders: maternal age (< 20, 20-34, > 34 years), gestational  
216 age(< 37, 37-41, > 41 weeks), years of education(0, 1-6, 7-9, 10-12, >12 years),  
217 marital status (without partner, with partner), parity (0, 1-2, > 2), previous CS (none,  
218 one or more), fetal presentation (vertex, breech and other), onset of labour  
219 (spontaneous, induced, no labour), birthweight (< 2500, 2500-3999,  $\geq$ 4000 g),  
220 number of neonates (singleton, multiple), chronic hypertension, preeclampsia and data  
221 collection year. Level of facility was classified as primary and secondary, tertiary and  
222 other referral level. We used gross domestic product (GDP) that were reported by the  
223 World Bank as a proxy for the socioeconomic condition for each country.

224 The main outcomes of this study included one primary and two secondary  
225 outcomes. Since severe maternal and neonatal morbidity and mortality are rare, we  
226 used a weighted perinatal adverse outcome index proposed by Mann et al.<sup>20</sup> as the  
227 primary outcome (Appendix Table 1). Several adverse outcomes listed in the  
228 Appendix Table 1 were not available in both surveys. Thus, our composite outcome

229 included Apgar score at five minutes < 7, maternal and/or neonatal death at hospital  
230 discharge or on the seventh day of life (alive/dead), maternal blood transfusion,  
231 admission of the mother to ICU/special care unit and neonatal conditions at birth  
232 (alive/fresh stillbirth). We calculated the perinatal adverse outcome index as the sum  
233 of weighted adverse outcome scores divided by the number of deliveries for each  
234 facility. Maternal and neonatal adverse outcome indexes were also created as the  
235 secondary outcomes. The maternal index was composed of maternal death at hospital  
236 discharge or on the seventh day of life (alive/dead), maternal blood transfusion, and  
237 admission of the mother to ICU/special care unit, while the neonatal index included  
238 Apgar score at five minutes < 7, neonatal death at hospital discharge or on the  
239 seventh day of life (alive/dead), and neonatal conditions at birth (alive/fresh stillbirth).

#### 240 **Statistical analysis**

241 In the current analysis, the facility was the unit of analysis. The exposure and  
242 covariates are all calculated as a rate or proportion in each facility. The covariates  
243 included the proportion of women in the facility aged 19 years or younger, 35 years or  
244 older, education less than seven years, more than 12 years, marital status, parity,  
245 previous caesarean delivery, fetal presentation, gestational age less than 37 weeks,  
246 more than 41 weeks, birthweight less than 2500 g, more than 4000 g, multiple births,  
247 chronic hypertension, preeclampsia, level of facility, and GDP.

248 Since the interval between the two surveys varied from country to country, we  
249 used a two-point estimator of Percent Change Annualized (PCA)<sup>21</sup> to examine how  
250 the annual rate of change in CS rate was associated with the annual rate of change in  
251 the incidence of adverse perinatal outcomes at the facility level between two surveys,  
252 where

$$253 \text{ PCA} = \left[ \left( \frac{\text{WHOMCS CS rate}}{\text{WHOCS CS rate}} \right)^{\frac{1}{\text{time difference (year)}}} - 1 \right] \times 100$$

254 A similar equation was used by WHO in calculating maternal mortality  
255 trends.<sup>6,22</sup> With the underlying assumption that the CS rate changed linearly, the  
256 statistical model was as follows:

257  $\text{PCA of adverse perinatal outcome composite index} = \text{PCA of CS rate} + \text{PCA of}$

258 covariates.

259 However, the PCA function became undefined when a zero rate was observed at  
260 either survey. To avoid this, we used a continuity correction by adding a small amount  
261 (0.0001) to facilities with a zero rate. This was particularly important for those  
262 variables with zero prevalence. All covariates and outcomes were aggregated and  
263 reported at "facility" level as described above, and then put into a linear mixed model  
264 where "country" was also considered as a level. The analyses were weighted by the  
265 average number of women of the two surveys for each facility. We also conducted  
266 stratified analyses according to the facility CS rate ( $\leq 10\%$  vs.  $>10\%$ ). To be more  
267 statistically conservative, the latter was calculated as the geometric mean of the CS  
268 rates (the square root of the CS rates) of the two surveys. All analyses were carried  
269 out with the statistical software SAS 9.1 (SAS Institute, Cary, NC, USA).  $P < 0.05$  was  
270 considered statistically significant.

## 271 **Results**

272 Figure 1 illustrates our selection process of the study population. In total, 217 844  
273 women in WHOGS and 227 734 women in WHOMCS from 259 facilities in 20 low-  
274 and middle-income countries were included in the following analysis. Appendix Table  
275 2 provides detailed information of the facilities by country.

276 Table 1 presents the characteristics of women at the individual level. These  
277 characteristics were reported because they were included in both surveys. More  
278 facilities became tertiary hospitals, increased from 31.1% (WHOGS) to 55.9%  
279 (WHOMCS). Women over 34 years changed from 9.9% to 10.7%. The proportion of  
280 education more than 12 years changed from 13.4% to 17.0%. In the WHOGS and  
281 WHOMCS surveys 43.7% and 45.5% of women were nulliparas, respectively. The  
282 proportion of women with previous CS changed from 10.5% to 12.9%. The  
283 prevalence of preeclampsia decreased from 2.8% to 2.1%, and chronic hypertension  
284 from 0.5% to 0.4%. Women with spontaneous onset of labor changed from 80.7% to  
285 77.6%. The overall CS rate increased from 27.0% to 31.7% between the two surveys.  
286 Multiple births had a reduction from 2.3% to 1.5%. Birthweight less than 2500g was  
287 from 10.5% in WHOGS to 11.1% in WHOMCS. In WHOGS, 95.0% had cephalic

288 fetal presentation compared with 95.5% in WHOMCS.

289

290 Table 2 presents the characteristics of the facilities in each survey. Due to a  
291 skewed distribution of most variables, we used median and interquartile range (Q1  
292 and Q3). The median CS rate by facility increased from 24.7% in WHOGS to 30.5%  
293 in WHOMCS.

294 During that period, the CS rate in these facilities increased by 3.99% annually,  
295 on average, while the incidence of adverse perinatal outcomes decreased by 4.59%  
296 annually. Figure 2 illustrates the relationship between PCA of CS rate and PCA of  
297 perinatal, maternal and neonatal adverse outcome indices at the facility level. The  
298 scatter plot shows no association between PCA of CS rate and PCA of adverse  
299 outcome. Table 3 quantitatively summarizes the crude and adjusted associations. An  
300 increase in CS rate was not significantly associated with a change in perinatal adverse  
301 outcome index in the crude analysis. When adjusted for a set of confounding variables,  
302 the results were similar ( $\beta=0.11$ , 95% CI: -0.71, 0.94,  $p=0.78$ ). Again, there was no  
303 significant association between PCA of CS rate and PCA of maternal and neonatal  
304 adverse outcomes ( $\beta=0.53$ , 95% CI: -0.06, 1.12,  $p=0.08$  for maternal adverse outcome  
305 index;  $\beta=-1.00$ , 95% CI: -8.23, 6.25,  $p=0.79$  for neonatal adverse outcome index).  
306 Furthermore, we stratified the CS rates by less or more than 10%. This stratification  
307 was based on our previous findings that when CS rate was below 10%, an increase in  
308 CS rate was associated with a decrease in mortality rates, but when CS rate was above  
309 10%, this association virtually disappeared. However, the current analysis failed to  
310 show any significant association regardless whether the CS rate was below or above  
311 10% or 19% in both multiparous and nulliparous women (also see Appendix Table 3  
312 and 4).

313

---

314

315 **Discussion**

316 Our study found that at the hospital level, increases in CS rates in low- and  
317 middle-income countries were not associated with changes in perinatal adverse  
318 outcome index irrespective of the baseline CS rate. This finding remained the same  
319 when we looked at the maternal and neonatal adverse outcome indexes separately.

320 As more and more developing countries have improved economic conditions in  
321 recent years, maternal and newborn mortality has decreased. Despite that mortality is  
322 considered to be a powerful socio-economic and health indicator within a population,  
323 death is a rare event and the isolated cases may not reflect the quality of obstetrical  
324 assistance.<sup>20,23</sup> Morbidity has been suggested as an alternative measure<sup>24</sup> Preventing  
325 morbidity and improving quality of care have become more important. Would a  
326 higher CS rate be necessary to achieve this goal? And how high should it be?  
327 Unfortunately, little is known in this regard.

328 Some European countries<sup>25</sup> and Japan<sup>26</sup> have maintained a CS rate below 20% at  
329 country level in the past two decades while continuing to improve perinatal outcomes.  
330 As these countries have some of the lowest perinatal mortality rates in the world, it  
331 may be assumed that generally speaking, CS rates may not have to go beyond 20% in  
332 order to achieve excellent perinatal outcomes.

333 In fact, the mode of delivery may play a less important role in improving  
334 perinatal outcomes at a population level. The CS rate is usually already much higher  
335 in the high risk pregnancies.<sup>27</sup> For example, in China, the CS rate in women with  
336 severe preeclampsia was 80% in comparison to 46.2% in the general  
337 population.<sup>27,28</sup> Will an even higher CS rate be necessary in these pregnancies?  
338 Probably not.

339 Ample evidence indicates that a high CS rate in some developing countries is due  
340 to CS without clear medical indication.<sup>29,30</sup> In our data, 85% of the facilities had a CS  
341 rate over 10%. It is likely that some of these CS were not medically indicated. A  
342 previous WHOOGS analysis<sup>31</sup> showed that a total of 1.0 percent of all deliveries had CS  
343 without medical indications, and the overall proportion of women delivering by CS

---

344 without medical indication ranged from 0.01 to 2.10%. In the Chinese institutions  
345 participating in WHOGS this figure was exceptionally higher at 11.6%.<sup>31</sup> The  
346 previous study demonstrated that CS without medical indication was associated with  
347 an increased risk of short-term adverse maternal outcomes.<sup>31</sup> Not only will it increase  
348 perinatal morbidity and mortality,<sup>32,33</sup> but also contribute to health care costs.<sup>34</sup> In UK,  
349 each additional vaginal birth instead of CS saves more than £1200.<sup>35</sup> For a  
350 lower-income country like Chile, the difference in cost between a vaginal delivery and  
351 a CS is about US\$350.<sup>36</sup> If unnecessary CS can be reduced, financial and human  
352 resources could be used in other parts of the health system.

353 It is worth mentioning that PCA was used as the main metrics of interest in this  
354 study. PCA is often used to measure trends in disease or mortality rates. For making  
355 comparisons or studying associations between very different rates, the absolute  
356 change in rates may not be appropriate. Thus, a relative change like PCA is better  
357 suited for such comparisons. This measure is often used in epidemiological literature  
358 and well recognized as a robust way of comparing rates.<sup>37</sup>

359 The current study is unique in that it linked the records of two large sequential  
360 WHO multi-country surveys to examine changes in CS rate and the changes in  
361 adverse maternal and perinatal outcomes in 20 low- and middle-income countries. A  
362 very large sample size in both surveys made the analysis possible, and results could  
363 potentially shed important light on changes in CS usage in those countries.

364 However, our study had several limitations. First, some additional variables that  
365 may be potential confounders for the association between CS rate and perinatal  
366 outcomes were included in only one survey but not both, precluding their use in the  
367 present study. Thus, potential residual confounding is possible. However, since our  
368 result is already negative, adjustments for more potential confounders would unlikely  
369 change our conclusion. Second, the number of facilities with a CS rate lower than 10%  
370 was small. The stratified analysis in this subgroup may have been underpowered.  
371 Third, the weighted adverse perinatal outcome index used in this study<sup>21</sup> lumped  
372 intrapartum fetal and neonatal deaths together. Given that the intrapartum stillbirth  
373 rate is considered as a good indicator for quality of intrapartum care, of which CS is

---

374 an important component, future studies are worth exploring “fresh stillbirth” rates in  
375 relation to CS.

376 Finally, it is important to point out that we used the Weighted Perinatal Adverse  
377 Outcome Index as our primary outcome but information on uterine rupture, birth  
378 trauma, return to the operating/labor and delivery room, admission to NICU (in  
379 neonates greater than 2500 g for over 24 hours), and third or fourth degree perineal  
380 tear was not available in both surveys. Thus, our index was based on 5 maternal and  
381 neonatal outcomes only. Nonetheless, we tried three different composite outcomes –  
382 severe maternal outcome, severe neonatal outcome and combined maternal and  
383 neonatal outcome. We also tested models using un-weighted adverse outcome indexes.  
384 The results were similar(not shown),reassuring the validity of our conclusion.

### 385 **Conclusions**

386 Our facility-based ecological analysis indicates that in low- and middle-income  
387 countries, the increases in CS rates were not associated with better perinatal outcomes  
388 regardless of whether the starting CS rate was already high or not.

389

### 390 **Authors’ contributions**

391 JZ conceived this study. YJ Zhao analysed the data. YJ Zhao and JZ co-drafted the  
392 article. J Zamora and JZ supervised the data analysis. JP Vogel, JP Souza, K Jayaratne,  
393 T Ganchimeg, E Ortiz-Panozo, B Hernandez, OT Oladapo, MR Torloni, N Morisaki,  
394 R Mori, C Pileggi-Castro, Ö Tunçalp, XM Shen, AP Betrán provided critical feedback  
395 on the interpretation of the results, helped with the writing of the article, and approved  
396 the final report. JZ is the guarantor.

### 397 **Funding**

398 The current analysis was partially funded by a grant from UNDP • UNFPA • UNICEF  
399 • WHO • World Bank Special Programme of Research, Development and Research  
400 Training in Human Reproduction, Department of Reproductive Health and Research,  
401 World Health Organization, Geneva, Switzerland and by the National Natural Science  
402 Foundation of China (Grant No. 81273091).The funder had no role in any aspect of  
403 the study. The authors have independence of research from the funders and have not

This article is protected by copyright. All rights reserved

---

404 been paid to write this article.

405

406 **Competing interests**

407 The authors declare that they have no competing interests.

408

409 **Ethical approval**

410 The WHOGS and WHOMCS were approved by the WHO Ethical Review Committee  
411 and the relevant ethical clearance bodies in participating countries and facilities.

412 Written consent from individual women was not needed because there was no contact  
413 between the data collectors (who extracted routine medical record data) and  
414 individual women.

415

416 **Acknowledgments**

417 This article represents the views of the named authors only, and does not represent the  
418 views of the World Health Organization. This work was supported by the National  
419 Natural Science Foundation of China (Grant No. 81273091) and the Department of  
420 Reproductive Health and Research, WHO, Geneva. The WHO Global Survey on  
421 Maternal and Perinatal Health was financially supported by the UNDP • UNFPA •  
422 UNICEF • WHO • World Bank Special Programme of Research, Development and  
423 Research Training in Human Reproduction (HRP), Department of Reproductive  
424 Health and Research, World Health Organization, Geneva, Switzerland; WHO; the  
425 Governments of China, India, and Japan; and the United States Agency for  
426 International Development (USAID). The WHO Multi-Country Survey on Maternal  
427 and Newborn Health was financially supported by the UNDP • UNFPA • UNICEF •  
428 WHO • World Bank Special Programme of Research, Development and Research  
429 Training in Human Reproduction (HRP), Department of Reproductive Health and  
430 Research, World Health Organization, Geneva, Switzerland; WHO; USAID; the  
431 Ministry of Health, Labour and Welfare of Japan; and Gynuity Health Projects. We  
432 thank all members of the WHO Global Survey on Maternal and Perinatal Health  
433 Research Network and the WHO Multi-Country Survey on Maternal and Newborn

This article is protected by copyright. All rights reserved

---

434 Health Research Network, including regional and country coordinators, data  
435 collection coordinators, facility coordinators, data collectors, and all staff of the  
436 participating facilities who made the surveys possible.

437 **References**

- 438 1 Alkema L, Chou D, Hogan D, et al. Global, regional, and national levels and  
439 trends in maternal mortality between 1990 and 2015, with scenario-based  
440 projections to 2030: a systematic analysis by the UN Maternal Mortality  
441 Estimation Inter-Agency Group. *Lancet* 2015. DOI: [http://dx.doi.org/10.1016/  
442 S0140-6736\(15\)00838-7](http://dx.doi.org/10.1016/S0140-6736(15)00838-7)
- 443 2 WHO, Neonatal and perinatal mortality, 2004: country, regional and global  
444 estimates. Geneva: World Health Organization; 2007.
- 445 3 WHO. Perinatal and neonatal mortality for the year 2000: Country, regional and  
446 global estimates. Geneva: World Health Organization; 2006.
- 447 4 Cousens S, Blencowe H, Stanton C, et al. National, regional and worldwide  
448 estimates of stillbirth rates in 2009 with trends since 1995: a systematic analysis.  
449 *Lancet* 2011; **377**:1319-1330.
- 450 5 World health statistics 2014 Part 3 Global health indicators.
- 451 6 Betrán AP, Ye J, Moller AB, Zhang J, Gülmezoglu AM, Torloni MR. The  
452 increasing trend in caesarean section rates: global, regional and national estimates:  
453 1990-2014. *PLoS One* 2016; 11(2):e0148343. doi: 10.1371/journal.pone.0148343
- 454 7 Betrán AP, Torloni MR, Zhang J, Ye J, Mikolajczyk R, Deneux-Tharaux C, et al.  
455 What is the optimal rate of caesarean section at population level? A systematic  
456 review of ecologic studies. *Reproductive Health* 2015;12:57.
- 457 8 Molina G, Weiser TG, Lipsitz SR, Esquivel MM, Uribe-Leitz T, Azad T, et al.  
458 Relationship Between Cesarean Delivery Rate and Maternal and Neonatal  
459 Mortality. *JAMA* 2015;314:2263-2270.
- 460 9 Ye J, Betrán AP, Guerrero VM, Souza JP, Zhang J. Searching for the optimal rate  
461 of medically necessary cesarean delivery. *Birth* 2014;**41**:237-244.
- 462 10 Ye J, Zhang J, Mikolajczyk, et al. Association between rates of caesarean section  
463 and maternal and neonatal mortality in the 21st century: a worldwide

- 
- 464 population-based ecological study with longitudinal data. *BJOG* 2015 Aug 24.  
465 doi: 10.1111/1471-0528.13592.
- 466 11 World Health Organization: Evaluating the quality of care for severe pregnancy  
467 complications. The WHO near-miss approach for maternal health. World Health  
468 Organization; 2011.
- 469 12 Pileggi-Castro C, Camelo JS Jr, Perdoná GC, et al. Development of criteria for  
470 identifying neonatal near-miss cases: analysis of two WHO multicountry  
471 cross-sectional studies. *BJOG* 2014; Suppl 1:110-8. doi: 10.1111/1471-  
472 0528.12637.
- 473 13 Firoz T, Chou D, von Dadelszen P, et al. Measuring maternal health: focus on  
474 maternal morbidity. *Bulletin of the World Health Organization* 2013; 91:794-796.  
475 doi: 10.2471/BLT.13.117564
- 476 14 ChavesSda C, Cecatti JG, Carroli G, et al. Obstetric transition in the World  
477 Health Organization Multicountry Survey on Maternal and Newborn Health:  
478 exploring pathways for maternal mortality reduction. *Rev Panam Salud Publica*  
479 2015;37: 203-210.
- 480 15 Souza JP, Tunçalp Ö, Vogel JP, et al. Obstetric transition: the pathway  
481 towards ending preventable maternal deaths. *BJOG* 2014; Suppl 1:1-4. doi:  
482 10.1111/ 1471-0528.12735.
- 483 16 Shah A, Faundes A, Machoki M, et al. Methodological considerations in  
484 implementing the WHO Global Survey for Monitoring Maternal and Perinatal  
485 Health. *Bulletin of the World Health Organization* 2008; **86**: 126–131.
- 486 17 Souza JP, Gulmezoglu AM, Vogel J, et al. Moving beyond essential interventions  
487 for reduction of maternal mortality (the WHO Multicountry Survey on Maternal  
488 and Newborn Health): a cross-sectional study. *Lancet* 2013;**381**:1747–1755.
- 489 18 Souza JP, Gulmezoglu AM, Carroli G, Lumbiganon P, Qureshi Z,WHOMCS  
490 Research Group. The World Health Organization multicountry survey on  
491 maternal and newborn health: study protocol. *BMC Health Services Research*  
492 2011;**11**:286.
- 493 19 Vogel JP, Betrán AP, Vindevoghel N, et al. Use of the Robson classification to

- 
- 494 assess caesarean section trends in 21 countries: a secondary analysis of two WHO  
495 multicountry surveys. *Lancet Global Health* 2015;**3**: e260–270.
- 496 20 Mann S, Pratt S, Gluck P, et al. Assessing quality in obstetrical care: development  
497 of standardized measures. *Joint Commission Journal on Quality and Patient*  
498 *Safety* 2006;**32**:497–505.
- 499 21 Fay MP, Tiwari RC, Feuer EJ, et al. Estimating Average Annual Percent Change  
500 for Disease Rates without Assuming Constant Change. *Biometrics* 2006; 62:  
501 847–854.
- 502 22 Kassebaum NJ, Bertozzi-Villa A, CoggeshallMS, et al. Global, regional, and  
503 national levels and causes of maternal mortality during 1990–2013: a systematic  
504 analysis for the Global Burden of Disease Study 2013. *Lancet* 2014; **384**:  
505 980–1004.
- 506 23 de Moraes AP, Barreto SM, Passos VM, et al. Severe maternal morbidity:  
507 a case-control study in Maranhao, Brazil. *Reprod Health* 2013;**10**:11. doi:  
508 10.1186/1742-4755-10-11.
- 509 24 World Health Organization: Beyond the numbers: reviewing maternal deaths  
510 and complications to make pregnancy safer. Geneva: WHO; 2004.
- 511 25 EURO-PERISTAT Project with SCPE and EUROCAT. European Perinatal Health  
512 Report. The health and care of pregnant women and babies in Europe in 2010.
- 513 26 Survey of Medical Institutions, Ministry of Health, Labour and Welfare and  
514 Survey of all the hospitals in Japan on patients, health care professionals and  
515 clinical practice in one month (September). Accessed August 7, 2015. Available  
516 at: <http://www.mhlw.go.jp/toukei/list/79-1a.html#01>.
- 517 27 Zhang YL, Li W, Xiao J & Chen SH. The complication and mode of delivery in  
518 Chinese women with severe preeclampsia: a retrospective study. *Hypertens*  
519 *Pregnancy* 2014;**33**:283–290.
- 520 28 Lumbiganon P, Laopaiboon M, Gülmezoglu AM, et al. Method of delivery and  
521 pregnancy outcomes in Asia: the WHO global survey on maternal and perinatal  
522 health 2007–08. *Lancet* 2010; **375**: 490–499.
- 523 29 Zhang J, Liu Y, Meikle S, Zheng J, Sun W, Li Z. Cesarean delivery on

- 
- 524 maternal request in southeast China. *Obstetrics and Gynecology* 2008; **111**:  
525 1077–1082.
- 526 30 Ramires de Jesus G1, Ramires de Jesus N, Peixoto-Filho FM, Lobato G.  
527 Caesarean rates in Brazil: what is involved? *BJOG* 2015; **122**: 606-609.
- 528 31 Souza JP, Gülmezoglu A, Lumbiganon P, et al. Caesarean section without  
529 medical indications is associated with an increased risk of adverse short-term  
530 maternal outcomes: the 2004-2008 WHO Global Survey on Maternal and  
531 Perinatal Health. *BMC Medicine* 2010; **8**:71-80.
- 532 32 Villar J, Valladares E, Wojdyla D, et al. Caesarean delivery rates and pregnancy  
533 outcomes: the 2005 WHO global survey on maternal and perinatal health in Latin  
534 America. *Lancet* 2006; **367**:1819–1829.
- 535 33 Villar J, Carroli G, Zavaleta N, et al. Maternal and neonatal individual risks and  
536 benefits associated with caesarean delivery: multicentre prospective study. *BMJ*  
537 2007;**335**:1025.
- 538 34 Henderson J, McCandlish R, Kumiega L, Petrou S. Systematic review of  
539 economic aspects of alternative modes of delivery. *BJOG* 2001;**108**:149–157.
- 540 35 The National Collaborating Centre for Women’s and Children’s Health.  
541 Caesarean section clinical guideline. *London: RCOG Press*, 2004.
- 542 36 Bonilla E. Scholarship report: midwife in Chile. *Jordemodern*1990; **103**:24–27.
- 543 37 Clegg LX, Hankey BF, Tiwari R, et al. Estimating average annual per cent change  
544 in trend analysis. *Statist Med* 2009; **28**:3670–3682.

**Table 1. Characteristics of women in the World Health Organization Global Survey and Multi-Country Survey**

|  | World Health Organization<br>Global Survey<br>N = 217 844 |       | World Health Organization<br>Multi-Country Survey<br>N = 227 734 |       |
|--|---|-------|--|-------|
|  | n   | %     | n  | %     |
|  | <b>Level of facility</b>                                  |       |  |       |
| <b>Primary and secondary</b>             | 148 965   | 68.4% | 94 219   | 41.4% |
| <b>Tertiary and other referral level</b> | 67 638  | 31.1% | 127 344  | 55.9% |
| <b>Missing</b>                           | 1 241   | 0.6%  | 6 171  | 2.7%  |
| <b>Maternal age</b>                      |   |       |  |       |
| <b>&lt;20 years</b>                      | 26 110  | 12.0% | 24 987   | 11.0% |
| <b>20 – 34 years</b>                     | 169 813   | 78.0% | 177 864  | 78.1% |
| <b>&gt;34 years</b>                      | 21 585  | 9.9%  | 24 433   | 10.7% |
| <b>Missing</b>                           | 336   | 0.2%  | 450  | 0.2%  |
| <b>Years of education</b>                |   |       |  |       |
| <b>0 year</b>                            | 17366   | 8.0%  | 23107  | 10.2% |
| <b>1 – 6 years</b>                       | 41639   | 19.1% | 29 343   | 12.9% |
| <b>7 – 9 years</b>                       | 49351   | 22.7% | 47153  | 20.7% |
| <b>10 – 12 years</b>                     | 69787   | 32.0% | 72723  | 32.0% |
| <b>&gt;12years</b>                       | 29 079  | 13.4% | 38750  | 17.0% |
| <b>Missing</b>                           | 10 622  | 4.9%  | 16 658   | 7.3%  |
| <b>Marital status</b>                    |   |       |  |       |
| <b>Without partner</b>                   | 24 114  | 11.1% | 23 273   | 10.2% |
| <b>With partner</b>                      | 193 232   | 88.7% | 202 839  | 89.1% |
| <b>Missing</b>                           | 498   | 0.2%  | 1 622  | 0.7%  |
| <b>Parity</b>                            |   |       |  |       |
| <b>0</b>                                 | 95 169  | 43.7% | 103 588  | 45.5% |
| <b>1 – 2</b>                             | 92 954  | 42.7% | 96 886   | 42.6% |

|                                    |               |         |       |         |       |
|------------------------------------|---------------|---------|-------|---------|-------|
|                                    | >2            | 28 986  | 13.3% | 26 973  | 11.8% |
|                                    | Missing       | 735     | 0.3%  | 287     | 0.1%  |
| <b>Previous caesarean delivery</b> |               |         |       |         |       |
|                                    | No            | 194 200 | 89.2% | 196 758 | 86.4% |
|                                    | Yes           | 22 840  | 10.5% | 29 373  | 12.9% |
|                                    | Missing       | 804     | 0.4%  | 1 603   | 0.7%  |
| <b>Preeclampsia</b>                |               |         |       |         |       |
|                                    | No            | 211 290 | 97.0% | 223 046 | 97.9% |
|                                    | Yes           | 6 195   | 2.8%  | 4 688   | 2.1%  |
|                                    | Missing       | 359     | 0.2%  | 0       | 0%    |
| <b>Chronic hypertension</b>        |               |         |       |         |       |
|                                    | No            | 216 388 | 99.3% | 226 811 | 99.6% |
|                                    | Yes           | 1 011   | 0.5%  | 923     | 0.4%  |
|                                    | Missing       | 355     | 0.2%  | 0       | 0%    |
| <b>Onset of labour</b>             |               |         |       |         |       |
|                                    | Spontaneous   | 175 826 | 80.7% | 176 660 | 77.6% |
|                                    | Induced       | 19 153  | 8.8%  | 22 891  | 10.1% |
|                                    | No labour     | 22 779  | 10.5% | 28 069  | 12.3% |
|                                    | Missing       | 86      | 0%    | 114     | 0.1%  |
| <b>Mode of delivery</b>            |               |         |       |         |       |
|                                    | Vaginal       | 159 082 | 73.0% | 155 466 | 68.3% |
|                                    | Caesarean     | 58 762  | 27.0% | 72 268  | 31.7% |
| <b>Number of neonates</b>          |               |         |       |         |       |
|                                    | Singleton     | 212 880 | 97.7% | 224 374 | 98.5% |
|                                    | Multiple      | 4 964   | 2.3%  | 3 342   | 1.5%  |
|                                    | Missing       | 0       | 0%    | 18      | 0%    |
| <b>Birthweight</b>                 |               |         |       |         |       |
|                                    | < 2500 gr     | 22 892  | 10.5% | 25 314  | 11.1% |
|                                    | 2500 – 3999gr | 189 423 | 87.0% | 196 264 | 86.2% |

---

|                                    |                      |         |       |         |       |
|------------------------------------|----------------------|---------|-------|---------|-------|
|                                    | <b>&gt; 3999gr</b>   | 5 529   | 2.5%  | 6 156   | 2.7%  |
| <b>Gestational age</b>             |                      |         |       |         |       |
|                                    | <b>&lt;37 weeks</b>  | 20 798  | 9.6%  | 15 865  | 7.0%  |
|                                    | <b>37 – 41 weeks</b> | 192 149 | 88.2% | 208 010 | 91.3% |
|                                    | <b>&gt;41 weeks</b>  | 4 897   | 2.3%  | 3 859   | 1.7%  |
| <b>Fetal presentation</b>          |                      |         |       |         |       |
|                                    | <b>Cephalic</b>      | 207 046 | 95.0% | 217 510 | 95.5% |
|                                    | <b>Non- Cephalic</b> | 10 603  | 4.9%  | 9 983   | 4.4%  |
|                                    | <b>Missing</b>       | 195     | 0.1%  | 241     | 0.1%  |
| <b>Apgar score at five minutes</b> |                      |         |       |         |       |
|                                    | <b>&lt;4</b>         | 2 373   | 1.1%  | 1 755   | 0.8%  |
|                                    | <b>4 – 6</b>         | 4 163   | 1.9%  | 3 242   | 1.4%  |
|                                    | <b>&gt; 6</b>        | 211 308 | 97.0% | 222 737 | 97.8% |

---

Note: all differences were statistically significant by chi-square test.

**Table 2. Characteristics of 259 facilities participating in both the World Health Organization Global Survey and Multi-Country Survey**

|                                    | World Health Organization | World Health Organization | P value |
|------------------------------------|---------------------------|---------------------------|---------|
|                                    | Global Survey             | Multi-Country Survey      |         |
|                                    | Median (Q1, Q3)           | Median (Q1, Q3)           |         |
| <b>Number of deliveries</b>        | 632 (356, 1 070)          | 701 (397, 1 157)          | <0.001  |
| <b>Maternal age</b>                |                           |                           |         |
| < 20 years                         | 11.3 (3.1, 18.2)          | 10.8 (3.5, 17.6)          | <0.001  |
| > 34 years                         | 10.7 (7.2, 14.6)          | 11.4 (8.3, 15.0)          | <0.001  |
| <b>Years of education</b>          |                           |                           |         |
| 0–6 years                          | 23.4 (7.7, 44.9)          | 16.7 (6.0, 38.7)          | <0.001  |
| > 12 years                         | 6.6 (2.5, 23.3)           | 11.9 (3.6, 25.8)          | <0.001  |
| <b>Marital status</b>              |                           |                           |         |
| Without partner                    | 5.0 (0.9, 17.1)           | 5.3 (1.0, 16.1)           | <0.001  |
| <b>Nulliparous</b>                 | 42.1 (34.4, 49.1)         | 44.1 (34.6, 52.3)         | <0.001  |
| <b>Previous caesarean delivery</b> | 9.3 (4.0, 14.0)           | 11.8 (6.4, 16.9)          | <0.001  |
| <b>Preeclampsia</b>                | 1.4 (0.4, 3.4)            | 1.1 (0.1, 2.6)            | <0.001  |
| <b>Chronic hypertension</b>        | 0.2 (0, 0.5)              | 0.1 (0, 0.4)              | <0.001  |
| <b>Onset of labour</b>             |                           |                           |         |
| Induced                            | 4.4 (1.6, 10.2)           | 3.7 (0.9, 9.6)            | <0.001  |
| No labour                          | 6.5 (1.4, 16.8)           | 9.0 (1.9, 19.8)           | <0.001  |
| <b>Caesarean delivery</b>          | 24.7 (12.8, 38.3)         | 30.5 (19.9, 43.4)         | <0.001  |
| <b>Multiple births</b>             | 2.1 (1.1, 3.3)            | 1.2 (0.7, 1.9)            | <0.001  |
| <b>Birth weight</b>                |                           |                           |         |
| < 2500 gr                          | 9.0 (6.1, 12.5)           | 7.8 (5.1, 12.1)           | <0.001  |
| > 4000 gr                          | 2.0 (0.8, 3.6)            | 2.1 (1.0, 4.9)            | <0.001  |
| <b>Gestational age</b>             |                           |                           |         |
| < 37 weeks                         | 7.1 (3.9, 10.9)           | 5.7 (2.9, 8.3)            | <0.001  |

---

|                                 |                |                |        |
|---------------------------------|----------------|----------------|--------|
| > 41 weeks                      | 1.5 (0.4, 3.5) | 0.8 (0.2, 2.2) | <0.001 |
| Non-cephalic fetal presentation | 4.2 (3.1, 5.8) | 4.0 (2.7, 5.4) | <0.001 |

---

Author Manuscript

**Table 3. Crude and adjusted associations between Percent Change Annualized (PCA) of caesarean section rate and PCA of adverse outcome index by levels of caesarean rate at the facility level**

| Linear Mixed Model #                              | Perinatal adverse outcome |      | Maternal adverse outcome |      | Neonatal adverse outcome |      |
|---|---------------------------|------|--------------------------|------|--------------------------|------|
|   | index <sup>b</sup>        |      | index <sup>c</sup>       |      | index <sup>d</sup>       |      |
|   | $\beta$ [95%CI]           | P    | $\beta$ [95%CI]          | P    | $\beta$ [95%CI]          | P    |
| <b>Overall Caesarean section rate</b>             | <b>(n=259)</b>            |      | <b>(n=259)</b>           |      | <b>(n=259)</b>           |      |
| Crude   | 0.29 [-0.49, 1.08]        | 0.46 | 0.54 [0.01, 1.06]        | 0.05 | 0.22 [-5.96, 6.40]       | 0.95 |
| Adjusted <sup>a</sup>                             | 0.11 [-0.71, 0.94]        | 0.78 | 0.53 [-0.06, 1.12]       | 0.08 | -1.00 [-8.23, 6.25]      | 0.79 |
| <b>Caesarean section rate<sup>s</sup> ≤10%</b>    | <b>(n=38)</b>             |      | <b>(n=38)</b>            |      | <b>(n=38)</b>            |      |
| Crude   | 0.06 [-0.75, 0.87]        | 0.87 | 0.87 [-0.01, 1.76]       | 0.05 | 0.15 [-0.11, 0.42]       | 0.25 |
| Adjusted <sup>a</sup>                             | -0.10 [-1.32, 1.43]       | 0.87 | 0.63 [-0.66, 1.92]       | 0.30 | -0.10 [-0.43, 0.23]      | 0.56 |
| <b>Caesarean section rate<sup>s</sup> &gt;10%</b> | <b>(n=221)</b>            |      | <b>(n=221)</b>           |      | <b>(n=221)</b>           |      |
| Crude   | 0.77 [-0.73, 2.27]        | 0.31 | -0.04 [-0.96, 0.88]      | 0.93 | 1.60 [-10.72, 13.91]     | 0.80 |
| Adjusted <sup>a</sup>                             | -1.04 [-3.07, 0.99]       | 0.31 | -0.90 [-2.27, 0.47]      | 0.20 | -8.11 [-27.50, 11.28]    | 0.41 |

# In linear mixed model, the dependent variable is the PCA of adverse outcome index, weighted by the average number of women in two facilities. We added a small amount (0.0001) when a zero rate was observed

<sup>s</sup> geometric mean of CS rate of two surveys


---

<sup>a</sup> Adjusted for PCA of women in the facility aged 19 years or younger, 35 years or older, education less than 7 years, education more than 12 years, marital status, parity, previous caesarean section, fetal presentation, year of survey, log gross domestic product, gestational age less than 37 weeks, gestational age more than 41 weeks, birthweight less than 2500g, birthweight more than 4000g, multiple births, chronic hypertension, preeclampsia and level of facility change (tertiary or other referral level) per year


<sup>b</sup> Perinatal adverse outcome index: Apgar score at five minutes < 7, maternal and/or neonatal death at hospital discharge or on the seventh day of life (alive/dead), maternal blood transfusion, admission of the mother to ICU/special care unit, neonatal conditions at birth(alive/fresh stillbirth).

<sup>c</sup> Maternal adverse outcome index: maternal death at hospital discharge or on the seventh day of life (alive/dead), maternal blood transfusion, admission of the mother to ICU/special care unit.

<sup>d</sup> Neonatal adverse outcome index: Apgar score at five minutes < 7, neonatal death at hospital discharge or on the seventh day of life (alive/dead), neonatal conditions at birth (alive/fresh stillbirth).




ppe\_12363\_f1.tif




ppe\_12363\_f2a.tif

Author Manuscript



ppe\_12363\_f2b.tif

Author Manuscript



ppe\_12363\_f2c.tif

Author Manuscript